Venture capitalist investor EMV Capital (EMVC) has led a c.£1.8m investment into its portfolio company ProAxsis – a spin-out from Queen’s University Belfast which focuses on diagnostics. Based in Northern Ireland, ProAxsis uses its proprietary ProteaseTag® technology to develop laboratory-based assays and rapid point-of-care tests for the measurement of active protease biomarkers associated with chronic…
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2024 All rights reserved LaingBuisson 
 has led a c.£1.8m investment into its portfolio company ProAxsis – a spin-out from Queen's University Belfast which focuses on diagnostics.){kind=link}